Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance, with revenue and EPS exceeding guidance. The Q&A highlights positive market expansion, particularly in the breast cancer market, and strong gross margins. The divestiture of low-margin products and strategic focus on high-growth areas are positives. While geopolitical and supply chain issues are noted, they are not seen as materially impactful. The lack of new partnerships or shareholder return plans is offset by optimistic guidance and market opportunities, leading to a positive sentiment prediction for the stock price.
Key Financial Performance
Total Revenue $381.9 million, up 7% year-over-year on a GAAP basis and up 5% year-over-year on a constant currency basis. Growth driven by 2.7% organic constant currency growth and contributions from acquisitions of Biolife and the C2 CryoBalloon device.
Organic Constant Currency Growth (excluding divested revenue) 3.7% in the first quarter. Impacted by the strategic divestiture of the DualCap product line in February 2026.
Non-GAAP Operating Margin 19.7%, increased 47 basis points year-over-year. Represents the highest first quarter operating margin in the company's history.
Non-GAAP EPS 9% growth year-over-year. Exceeded the high end of expectations.
Free Cash Flow $25 million, an increase of 26% year-over-year.
Revenue by Geography U.S. sales increased $14.5 million or 6.8%, and international sales increased $4.1 million or 3% year-over-year.
Revenue by Product Category Foundational products increased $10.1 million or 4%, and therapeutic products increased $8.5 million or 7%. Organic growth in foundational products was 1.5%, and therapeutic products were 5.2%.
OEM Sales Declined 14% year-over-year in Q1. Impacted by macro environment trends in the APAC region and inventory destocking dynamics in the U.S.
Gross Margin 53.2%, down 20 basis points year-over-year. Included a $4.6 million impact from tariffs.
Operating Income $75.3 million, increased $6.9 million or 10% year-over-year. Operating margin was 19.7%, up 47 basis points year-over-year.
Net Income $56.7 million or $0.94 per share, compared to $52.9 million or $0.86 per share in the prior year period. Exceeded the high end of guidance range by $3.7 million and $0.07, respectively.
Cash and Cash Equivalents $488.1 million as of March 31, 2026, compared to $446.4 million as of December 31, 2025.
Total Debt Obligations $747.5 million as of March 31, 2026, unchanged from December 31, 2025.
Net Leverage Ratio 1.6x on an adjusted basis as of March 31, 2026.
Free Cash Flow Generation $24.7 million in Q1, driven by strong cash flow and proceeds from the DualCap product line divestiture.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Resilience Through-the-Scope (TTS) Esophageal Stent: Launched in the U.S. for treating esophageal fistulas and structures caused by malignant tumors. Designed for high migration resistance and precise placement, targeting growth in the endoscopy platform.
View Point Medical Acquisition: Acquired for $140 million, including $90 million in cash. Adds OneMark Detection Imaging System and Tissue Markers to the portfolio, expanding oncology offerings and addressing 1.3 million procedures annually in the U.S.
Oncology Market Expansion: The acquisition of View Point Medical triples the addressable procedure opportunity for the oncology business, enhancing the portfolio with innovative diagnostic and localization solutions.
Revenue Growth: Q1 revenue reached $381.9 million, up 7% year-over-year on a GAAP basis, driven by organic growth and acquisitions.
Profitability: Non-GAAP operating margin increased to 19.7%, the highest Q1 margin in company history. Non-GAAP EPS grew by 9%.
Cash Flow: Generated $25 million in free cash flow, a 26% year-over-year increase.
Revenue Reporting Realignment: Shifted to reporting revenue in two categories: foundational and therapeutic products, to streamline internal and external communication.
Platform-Based Operating Model: Introduced eight platforms (e.g., Access, Oncology, Endoscopy) co-led by marketing and R&D leads to enhance alignment and growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impact: The company faces a significant tariff impact, with a projected 12-month tariff cost of approximately $15 million or $0.19 per share in 2026. This represents an increase from $9 million or $0.12 per share in 2025. The evolving tariff situation and potential retaliatory actions could further impact financial performance.
OEM Sales Decline: OEM sales declined 14% year-over-year in Q1 2026, driven by macroeconomic challenges in the APAC region and inventory destocking dynamics in the U.S. This decline poses a risk to revenue stability and growth.
Acquisition Dilution: The acquisition of View Point Medical is expected to dilute 2026 non-GAAP EPS by $0.05. While the acquisition has long-term strategic benefits, the short-term financial impact could affect profitability.
Divestiture Impact: The divestiture of the DualCap product line represents a year-over-year revenue headwind of approximately 130 basis points to total constant currency revenue growth in 2026.
Macroeconomic Challenges: Sales to OEM customers outside the U.S., particularly in the APAC region, are impacted by macroeconomic conditions, which could continue to affect demand trends.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For fiscal year 2026, the company expects total GAAP net revenue growth in the range of 6.3% to 7.8% year-over-year and 5.6% to 7% year-over-year on a constant currency basis. Excluding inorganic revenue, organic constant currency growth is projected at 4.5% to 6% year-over-year.
Product Categories: Sales of foundational products are expected to increase in the mid-single digits year-over-year, while sales of therapeutic products are projected to grow in the high single digits year-over-year.
Acquisition Impact: The acquisition of View Point Medical is expected to contribute $2 million to $4 million in revenue for 2026 and dilute non-GAAP EPS by approximately $0.05. Longer-term, the acquisition is projected to be accretive to the company's multiyear growth and profitability profile.
Second Quarter 2026 Guidance: Total revenue is expected to range between $400 million and $410 million, representing 5% to 7% year-over-year growth on a GAAP basis and 4% to 7% on a constant currency basis. Non-GAAP EPS is projected to range between $0.90 and $1.
Profitability: Non-GAAP diluted earnings per share for 2026 are expected to range between $4.01 and $4.15, reflecting a 5% to 8% increase year-over-year. Non-GAAP operating margins for Q2 2026 are expected to range between 18.7% and 20.4%.
Tariff Impact: The company anticipates a 12-month tariff impact of approximately $15 million or $0.19 per share for 2026, compared to $9 million or $0.12 per share in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any updates on WRAPSODY's progress?
A:Martha Aronson stated that they are pleased with WRAPSODY's progress. They reset their go-to-market strategy at the end of last year and are tracking on their revised 2026 guidance of $7 million for WRAPSODY.
Q:Are you seeking refunds for tariffs paid last year and earlier this year?
A:Raul Parra confirmed that they have started the process of reimbursement for tariffs. However, the administration can still challenge the reimbursement through May. They will provide an update in the second quarter call.
Q:What is driving the revenue growth for View Point from $2-4 million this year to $14-16 million next year?
A:Martha Aronson explained that the growth is driven by market expansion opportunities in the breast cancer market, particularly with the addition of OneMark, which expands the applicable market 3-4 times. Raul Parra added that the 2027 guidance includes strong gross margins of 70% and is accretive on both top and bottom lines.
Q:Can you clarify the growth expectations for the OEM business?
A:Raul Parra stated that they expect mid-single-digit growth for the OEM business in Q2 and are confident in achieving this growth for the year. He emphasized that the OEM business remains healthy despite quarter-to-quarter fluctuations.
Q:What is the status of the supply chain issues in the cardiac business?
A:Raul Parra mentioned that the supply chain issue turned into a recall, but it is immaterial to their 2026 financial results. They are on track to have the product back on the market.
Q:What is the impact of geopolitical issues in the Middle East on revenue and input costs?
A:Raul Parra stated that they have not received price increases from vendors but are seeing fuel surcharges. They left $1.5 million of revenue on the table due to shipping issues but feel optimistic about their 2026 guidance.
Q:What are the assumptions for China and Asia Pacific (APAC) contributions?
A:Raul Parra stated that APAC sales were up 1% in Q1, with China sales increasing by 2% year-over-year. They expect low single-digit growth for China in 2026 due to volume-based purchasing.
Q:How are you managing operating margins and expenses?
A:Raul Parra highlighted better-than-expected gross margins and controlled operating expenses, leading to a strong start in Q1. Martha Aronson credited the finance team for ensuring discipline across the organization.
Q:What is the strategy for OneMark and its impact on SCOUT?
A:Martha Aronson stated that OneMark is seen as a market expansion play rather than cannibalistic to SCOUT. It provides a better and best offering, targeting specific accounts to expand the market.
Q:What drove the gross margin performance despite tariff expenses?
A:Raul Parra attributed the performance to a mix of selling the right products at the right price, acquisitions, and divesting low-margin products like DualCap.
Q:Why did inventory increase by $20 million in the quarter?
A:Raul Parra explained that the increase was due to acquisitions, building safety stocks, and ensuring coverage for expected company performance.
Q:What is the distribution strategy for OneMark post-acquisition?
A:Martha Aronson stated that View Point had a smaller organization, and the integration into Merit Medical's team will enhance product awareness and account targeting.
Q:What are the key areas for future acquisitions?
A:Martha Aronson emphasized strategic fit and financial metrics for acquisitions, focusing on tuck-ins or bolt-ons rather than transformational deals.
Q:What is the impact of the Medtronic distribution deal on growth?
A:Raul Parra stated that the deal is built into their guidance for the year and contributes to their confidence in mid-single-digit growth for the OEM business.
Q:Would you consider a share repurchase given the stock's current valuation?
A:Raul Parra stated that this is a Board-level decision, and the focus remains on M&A, CGI goals, and delivering long-term sustainable growth.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about whether the outcomes of the OneMark trial would change the strategy with SCOUT, stating only that they are excited about the enhanced product offering and physician preference.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
OneMark system
Point Medical
Resilience
Stent
TTS Esophageal
Vascular Intervention
Vascular intervention
View Point
acquisition Merit
acquisition View
biopsy
cash closing
combination
consideration
currency respect
divestiture
imaging
increase sale
lead
localization
month acquisition
month tariff
non dilution
oncology endoscopy
oncology platform
placement tissue
platform result
platform year
procedure
profitability cash
rationale
sale compound
therapy oncology
tissue marker
tissue tumor
MMSI Transcript
Merit Medical Systems, Inc. (MMSI) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary indicates strong financial performance, with revenue and EPS exceeding guidance. The Q&A highlights positive market expansion, particularly in the breast cancer market, and strong gross margins. The divestiture of low-margin products and strategic focus on high-growth areas are positives. While geopolitical and supply chain issues are noted, they are not seen as materially impactful. The lack of new partnerships or shareholder return plans is offset by optimistic guidance and market opportunities, leading to a positive sentiment prediction for the stock price.
Merit Medical Systems, Inc. (MMSI) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call reveals solid financial performance with record-high gross margins, strong operating income growth, and positive revenue projections, especially in the cardiovascular and endoscopy segments. Despite some concerns over OEM revenue and cautious Q1 2026 guidance, the company's strategic acquisitions and optimistic long-term outlook for Rhapsody and other products support a positive sentiment. The market cap suggests a moderate reaction, leading to a 2%-8% stock price increase prediction.
Merit Medical Systems, Inc. (MMSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary reflects a positive outlook with strong financial metrics, optimistic guidance, and strategic focus on growth. The Q&A section confirmed strong free cash flow and potential for acquisitions, while addressing concerns about expenses and market dynamics. The company's clear strategy for growth, including WRAPSODY and CryoBalloon C2, supports a positive sentiment. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range, over the next two weeks.
MMSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
